

FDA Staff Manual Guides, Volume I – Organizations and Functions

Department of Health and Human Services

Food and Drug Administration

Center for Biologics Evaluation and Research

Office of Therapeutic Products

Office of Plasma Protein Therapeutics CMC

Division of Plasma Derivatives

Effective Date: March 15th, 2025

1. Division of Plasma Derivatives (DCBGHB).

- A. Evaluates Biologic License Applications (BLAs) for plasma protein products defined as plasma-derived and recombinant products to treat coagulation disorders, immunodeficiencies, autoimmune conditions, and plasma protein deficiencies. Products also include Specific Immune Globulins for prevention and treatment of viral and bacterial diseases, envenomations, and intoxications. Develops policy and formulates recommendations on BLAs consistent with the applicable laws and Center policies.
- B. Reviews Investigational New Drug Applications (INDs), Investigational Device Exemptions (IDEs), 510(k)s, and Pre-market Approval Applications (PMAs) for plasma protein products.
- C. Evaluates, with other Office components, reports on biological product deviations and adverse events submitted in association with the use of marketed products.
- D. Participates in the inspection of manufacturing facilities of plasma protein products.
- E. Contributes to recommendations on activities such as market withdrawals, recalls, and other compliance actions, in cooperation with other Offices in the Center.
- F. Provides expert scientific and technical advice and assistance to other Center components and to the Food and Drug Administration (FDA) on products and issues related to coagulation disorders, immunodeficiency, autoimmunity, inherited plasma protein deficiencies, and certain viral and bacterial diseases as

well as products for treatment of intoxications and envenomations.

- G. Develops policies and procedures applicable to the review and evaluation of INDs, BLAs and products regulated by the Office, in the absence of Center-level policies and procedures.
- H. Performs consultative and collaborative reviews of product information and data in BLAs, BLA amendments and supplements, and INDs, IDEs, 510(k)s, PMAs in response to request from other Center components.
- I. Initiates and conducts mission-related, scientific research related to plasma protein products for the treatment of bleeding disorders and other conditions,
- J. Initiates and participates in development of reference standards and methods, in conjunction with other Center components, governmental and non-governmental organizations, and international regulatory agencies.
- K. Initiates, organizes, and conducts workshops and formally communicates with international regulatory authorities to address safety, potency, and efficacy issues related to regulated products in collaboration with other Center components.

2. Plasma Derivatives Branch 1 (DCBGHB1).

- A. Reviews BLAs, INDs related to plasma-derived and recombinant plasma protein products used for the treatment of immunodeficiencies, autoimmune conditions, and plasma protein deficiencies, as well as for prevention and treatment of viral and bacterial diseases, envenomations, and intoxications.
- B. Performs scientific research on the biology, biochemistry, immunology, molecular and cell biology related to products used for the treatment of immunodeficiencies, autoimmune conditions, and plasma protein deficiencies, as well as for prevention and treatment of viral and bacterial diseases, envenomations, and intoxications.
- C. Participates in inspections of manufacturing facilities of plasma-derived and recombinant plasma protein products.
- D. Initiates and participates in the development of reference standards and analytical methods, in conjunction with other Center components, governmental and non-governmental organizations, and international regulatory agencies.
- E. Evaluates reports on biological product deviation and adverse events submitted in association with the manufacture and use of marketed products.
- F. Provides expert scientific and technical advice and assistance to other Center or

FDA components on products and issues related to treatment of immunodeficiencies, autoimmune conditions, and plasma protein deficiencies, as well as for prevention and treatment of viral and bacterial diseases, envenomations, and intoxications.

- G. Participates in working groups or committees to develop guidance documents, policies and procedures applicable to the review of the products regulated by the Office.
- H. Performs consultative and collaborative reviews of chemistry, manufacturing, and controls (CMC) information in product applications in response to request from other FDA components.
- I. Evaluates and takes action to prevent or ameliorate product shortages, in conjunction with relevant Offices in the Center.

3. Plasma Derivatives Branch 2 (DCBGHB2).

- A. Reviews BLAs, INDs related to plasma-derived and recombinant plasma protein products used for the treatment of immunodeficiencies, autoimmune conditions, and plasma protein deficiencies, as well as for prevention and treatment of viral and bacterial diseases, envenomations, and intoxications.
- B. Performs scientific research on the biology, biochemistry, immunology, molecular and cell biology related to products used for the treatment of immunodeficiencies, autoimmune conditions, and plasma protein deficiencies, as well as for prevention and treatment of viral and bacterial diseases, envenomations, and intoxications.
- C. Participates in inspections of manufacturing facilities of plasma-derived and recombinant plasma protein products.
- D. Initiates and participates in the development of reference standards and analytical methods, in conjunction with other Center components, governmental and non-governmental organizations, and international regulatory agencies.
- E. Evaluates reports on biological product deviation and adverse events submitted in association with the manufacture and use of marketed products.
- F. Provides expert scientific and technical advice and assistance to other Center or FDA components on products and issues related to treatment of immunodeficiencies, autoimmune conditions, and plasma protein deficiencies, as well as for prevention and treatment of viral and bacterial diseases,


envenomations and intoxications.

- G. Participates in working groups or committees to develop guidance documents, policies and procedures applicable to the review of the products regulated by the Office.
- H. Performs consultative and collaborative reviews of CMC information in product applications in response to request from other FDA components.
- I. Evaluates and takes action to prevent or ameliorate product shortages, in conjunction with relevant Offices in the Center.

4. Authority and Effective Date.

The functional statements for the Division of Plasma Derivatives were approved by the Chief Financial Officer and effective on March 15th, 2025.

**Department of Health and Human Services
Food and Drug Administration
Center for Biologics Evaluation and Research
Office of Therapeutic Products
Office of Plasma Protein Therapeutics CMC
Division of Plasma Derivatives**



Staff Manual Guide 1218A.42
Organizations and Functions
Effective Date: September 16, 2022

The following is the Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Therapeutic Products, Office of Plasma Protein Therapeutics CMC, Division of Plasma Derivatives organization structure depicting all the organizational structures reporting to the Director.

Division of Plasma Derivatives (DCBGHB)